PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
33419802-5	2021	RESULTS: Nelfinavir inhibited SCLC cell proliferation and induced cell death in vitro, which was caused by induction of the unfolded protein response (UPR), inhibition of mammalian/mechanistic target of rapamycin (mTOR) activation, and reduction in the expression of SCLC-related molecules such as achaete-scute homolog 1 (ASCL1).	Nelfinavir	9-19	mechanistic target of rapamycin kinase	Homo sapiens	171-212	
33419802-5	2021	RESULTS: Nelfinavir inhibited SCLC cell proliferation and induced cell death in vitro, which was caused by induction of the unfolded protein response (UPR), inhibition of mammalian/mechanistic target of rapamycin (mTOR) activation, and reduction in the expression of SCLC-related molecules such as achaete-scute homolog 1 (ASCL1).	Nelfinavir	9-19	mechanistic target of rapamycin kinase	Homo sapiens	214-218	
30275179-7	2018	Nelfinavir was also found to increase the expression of the mammalian target of rapamycin (mTOR) inhibitor AMP-activated protein kinase (AMPK) and inhibited the panobinostat-activated mTOR pathway.	Nelfinavir	0-10	mechanistic target of rapamycin kinase	Homo sapiens	60-89	
30275179-7	2018	Nelfinavir was also found to increase the expression of the mammalian target of rapamycin (mTOR) inhibitor AMP-activated protein kinase (AMPK) and inhibited the panobinostat-activated mTOR pathway.	Nelfinavir	0-10	mechanistic target of rapamycin kinase	Homo sapiens	91-95	
30275179-7	2018	Nelfinavir was also found to increase the expression of the mammalian target of rapamycin (mTOR) inhibitor AMP-activated protein kinase (AMPK) and inhibited the panobinostat-activated mTOR pathway.	Nelfinavir	0-10	mechanistic target of rapamycin kinase	Homo sapiens	184-188	
21811091-5	2011	We evaluated tumor growth delay and confirmed nelfinavir"s effect on the PI3K-AKT-mTOR pathway in a hind-flank model.	Nelfinavir	46-56	mechanistic target of rapamycin kinase	Homo sapiens	82-86	
23916134-0	2013	Nelfinavir and bortezomib inhibit mTOR activity via ATF4-mediated sestrin-2 regulation.	Nelfinavir	0-10	mechanistic target of rapamycin kinase	Homo sapiens	34-38	
23916134-4	2013	In this study, the treatment of cancer cells with ER stress-inducing drug nelfinavir resulted in the expression of endogenous mTOR inhibitor sestrin-2 (SESN2).	Nelfinavir	74-84	mechanistic target of rapamycin kinase	Homo sapiens	126-130	
23916134-9	2013	Accordingly, cancer cells treated with the ER stress-inducing agent nelfinavir showed reduced mTOR activity and associated increases in the expression levels of ATF4 and SESN2.	Nelfinavir	68-78	mechanistic target of rapamycin kinase	Homo sapiens	94-98	
23916134-11	2013	mTOR inhibition by nelfinavir, which is currently in clinical trials for cancer patients, may also explain its observed ability to induce autophagy, growth arrest, and radiosensitization in cancer cells.	Nelfinavir	19-29	mechanistic target of rapamycin kinase	Homo sapiens	0-4	
22338016-0	2012	Akt inhibitors MK-2206 and nelfinavir overcome mTOR inhibitor resistance in diffuse large B-cell lymphoma.	Nelfinavir	27-37	mechanistic target of rapamycin kinase	Homo sapiens	47-51	
22338016-10	2012	Nelfinavir and MK-2206, chosen for their Akt-inhibitory properties, yielded synergistic inhibition of cell viability in combination with rapamycin in DLBCL cell lines, and potently inhibited phosphorylation of Akt and downstream targets of activated mTOR.	Nelfinavir	0-10	mechanistic target of rapamycin kinase	Homo sapiens	250-254	
21811091-10	2011	Decreased phospho-S6 on Western blotting in vitro and immunohistochemistry in vivo demonstrated nelfinavir inhibition of the PI3K-AKT-mTOR pathway.	Nelfinavir	96-106	mechanistic target of rapamycin kinase	Homo sapiens	134-138